| Carcinoma, Bronchogenic |
NCT02726568: High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases |
|
|
| Recruiting | 2 | 30 | RoW | Icotinib, SRS | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer, Brain Metastases | 12/21 | 12/22 | | |
NCT01588028: A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1/2 | 36 | US | CH5424802 | Hoffmann-La Roche | ALK-Rearranged Non-Small Cell Lung Cancer | 09/15 | 09/15 | | |
|
|
|
NCT01279798: Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) |
|
|
| No Longer Available | N/A | | US | Lucanix® (belagenpumatucel-L), Lucanix | NovaRx Corporation | Non-small Cell Lung Cancer | | | | |
NCT02271139: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy |
|
|
| No Longer Available | N/A | | US | Alectinib | Genentech, Inc. | Non-Small Cell Lung Cancer | | | | |
NCT02824094: Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC |
|
|
| No Longer Available | N/A | | Japan | crizotinib | Pfizer | Neoplasms, Carcinoma, Non-Small-Cell Lung | | | | |
NCT02784158: An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer |
|
|
| No Longer Available | N/A | | US | Brigatinib, AP26113 | Ariad Pharmaceuticals | Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma | | | | |
NCT02547675: Rociletinib (CO-1686) USA Expanded Access Program |
|
|
| No Longer Available | N/A | | US | Rociletinib, CO-1686 | Clovis Oncology, Inc. | Non-small Cell Lung Cancer | | | | |